Aspire Biopharma Holdings (ASBP) Interest Expenses (2024 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Interest Expenses of $1.6 million for Q1 2026, up 450.24% year-over-year from $289931.0 in Q1 2025, and down 74.41% quarter-over-quarter from $6.2 million in Q4 2025.
Aspire Biopharma Holdings (ASBP) Interest Expenses (2024 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Interest Expenses for 3 consecutive years, with $1.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 450.24% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $9.8 million (up 2815.53% YoY), while the FY2025 annual figure was $8.5 million, up 856.82% from the prior year.
- Interest Expenses eased to $1.6 million in Q1 2026 per ASBP's latest filing, from $6.2 million in the prior quarter.
- Across five years, Interest Expenses topped out at $6.2 million in Q4 2025 and bottomed at -$72083.0 in Q4 2024.
- Historically, Interest Expenses has averaged $1.3 million across 3 years, with a median of $408912.0 in 2025.
- On a YoY basis, Interest Expenses climbed as much as 8747.52% in 2025 and fell as far as 58.16% in 2025.
- Aspire Biopharma Holdings' Interest Expenses stood at -$72083.0 in 2024, then jumped by 8747.52% to $6.2 million in 2025, then tumbled by 74.41% to $1.6 million in 2026.
- Business Quant data shows ASBP's Interest Expenses at $1.6 million in Q1 2026, $6.2 million in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 75,000.00 |
| Jun 30, 2026 | 75,000.00 |
| Mar 31, 2026 | 1.60 Mn |
| Mar 31, 2026 | 1.60 Mn |
| Dec 31, 2025 | 6.23 Mn |
| Dec 31, 2025 | 6.23 Mn |
| Sep 30, 2025 | 1.48 Mn |
| Sep 30, 2025 | 1.48 Mn |
| Jun 30, 2025 | 527,893.00 |
| Jun 30, 2025 | 527,893.00 |
| Mar 31, 2025 | 289,931.00 |
| Mar 31, 2025 | 289,931.00 |
| Dec 31, 2024 | -72,083.00 |
| Dec 31, 2024 | -72,083.00 |
| Jun 30, 2024 | 119,540.00 |
| Jun 30, 2024 | 119,540.00 |
| Mar 31, 2024 | 183,310.00 |
| Mar 31, 2024 | 183,310.00 |